The company said net earnings for Q2 2025 fell to $599 million ($1.11 per diluted share) from $1.8 billion ($3.10) a year earlier, and that it had net investment losses of $421 million.

1. 01

   The company said net earnings for Q2 2025 fell to $599 million ($1.11 per diluted share) from $1.8 billion ($3.10) a year earlier, and that it had net investment losses of $421 million.

2. 02

   Aflac said adjusted earnings for Q2 were $957 million, down 7.5% from $1.0 billion a year earlier, and that adjusted earnings per diluted share fell 2.7% to $1.78.

3. 03

   The company said total new annualized premium sales for Q2 rose 23.2% to ¥20.7 billion ($143 million), and it cited strong sales of the new cancer insurance product Miraito as the main driver.

4. 04

   Aflac said it repurchased 7.9 million common shares for $829 million in Q2, and its board declared a Q3 dividend of $0.58 per share.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.